Description

Legend Biotech’s In Vivo CAR-T Pipeline: Could BCMA And GPRC5D Reset The Story?

Legend Biotech reported its first quarter of 2026 financial and operational results marked by continued commercial expansion of its lead product, CARVYKTI, and advancing development of its broader pipeline, including several in vivo CAR-T therapy programs. During the quarter, CARVYKTI generated approximately $597 million in net trade sales, representing a 52% year-over-year increase. Growth drivers included a 36% increase in U.S. sales and over 200% growth internationally, with availability now expanded across 18 markets and more than 300 treatment sites globally. The company highlighted a shift in the multiple myeloma treatment paradigm favoring earlier use of CAR-T therapies, with 41% of U.S. apheresis volumes originating from second and third line patients compared to 29% a year earlier. This trend is supported by community adoption and increased referrals, with 148 authorized U.S. treatment centers, approximately one-third of which are community or regional hospitals.